Literature DB >> 12224504

Inhibition of the MHC class II antigen presentation pathway by human cytomegalovirus.

D C Johnson1, N R Hegde.   

Abstract

Human cytomegalovirus (HCMV) causes serious disease in immunocompromised individuals. Normally, anti-HCMV immune response controls virus replication following reactivation from latency. However, HCMV, like other large herpesviruses, encodes immune evasion proteins that allow the virus to replicate, for a time or in specific tissues, and produce viral progeny in the face of robust host immunity. HCMV glycoproteins US2, US3, US6 and US11 all inhibit different stages of the MHC class I antigen presentation pathway and can reduce recognition by CD8+ T lymphocytes. Here, we discuss two novel inhibitors of the MHC class II antigen presentation pathway, HCMV glycoproteins US2 and US3. Both US2 and US3 can inhibit presentation of exogenous protein antigens to CD4+ T lymphocytes in in vitro assays. US2 causes degradation of MHC class II molecules: HLA-DR-alpha and HLA-DM-alpha, as well as class I heavy chain (HC), but does not affect DR-beta or DM-beta chains. Mutant forms of US2 have been constructed that can bind to DR-alpha and class I HC but do not cause their degradation, separating the binding step from other processes that precede degradation. We also found evidence that US2-induced degradation of class I and II proteins involves a cellular component, other than Sec61, that is limiting in quantity. Unlike US2, US3 binds newly synthesized class II alpha/beta complexes, reducing the association with the invariant chain (Ii) and causing mislocalization of class II complexes in cells. US3 expression reduces accumulation of class II complexes in peptide-loading compartments and loading of peptides. Since US2 and US3 are expressed solely within HCMV-infected cells, it appears that these viral proteins have evolved to inhibit presentation of endogenous, intracellular viral antigens to anti-HCMV CD4+ T cells. This is different from how the MHC class II pathway is normally viewed, as a pathway for presentation of exogenous, extracellular proteins. The existence of these proteins indicates the importance of class II-mediated presentation of endogenous antigens in signalling virus infection to CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12224504     DOI: 10.1007/978-3-642-59421-2_7

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  18 in total

1.  Human cytomegalovirus pUL83 stimulates activity of the viral immediate-early promoter through its interaction with the cellular IFI16 protein.

Authors:  Ileana M Cristea; Nathaniel J Moorman; Scott S Terhune; Christian D Cuevas; Erin S O'Keefe; Michael P Rout; Brian T Chait; Thomas Shenk
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

Review 2.  Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection.

Authors:  Michael L Freeman; Michael M Lederman; Sara Gianella
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

Review 3.  Cytomegalovirus and HIV Persistence: Pouring Gas on the Fire.

Authors:  Aaron Christensen-Quick; Christophe Vanpouille; Andrea Lisco; Sara Gianella
Journal:  AIDS Res Hum Retroviruses       Date:  2017-11       Impact factor: 2.205

4.  Herpes simplex virus 1 glycoprotein B and US3 collaborate to inhibit CD1d antigen presentation and NKT cell function.

Authors:  Ping Rao; Hong Thanh Pham; Arpita Kulkarni; Yang Yang; Xueqiao Liu; David M Knipe; Peter Cresswell; Weiming Yuan
Journal:  J Virol       Date:  2011-06-08       Impact factor: 5.103

5.  Human cytomegalovirus US2 causes similar effects on both major histocompatibility complex class I and II proteins in epithelial and glial cells.

Authors:  Nagendra R Hegde; David C Johnson
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

6.  Binding of human cytomegalovirus US2 to major histocompatibility complex class I and II proteins is not sufficient for their degradation.

Authors:  Mathieu S Chevalier; Gwynn M Daniels; David C Johnson
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

7.  Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation.

Authors:  Nagendra R Hegde; Roman A Tomazin; Todd W Wisner; Claire Dunn; Jessica M Boname; David M Lewinsohn; David C Johnson
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

8.  Herpes Simplex Virus 1 Specifically Targets Human CD1d Antigen Presentation To Enhance Its Pathogenicity.

Authors:  Ping Rao; Xiangshu Wen; Jae Ho Lo; Seil Kim; Xin Li; Siyang Chen; Xiaotian Feng; Omid Akbari; Weiming Yuan
Journal:  J Virol       Date:  2018-10-29       Impact factor: 5.103

9.  Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers.

Authors:  M B Reeves; P A MacAry; P J Lehner; J G P Sissons; J H Sinclair
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-28       Impact factor: 11.205

10.  Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2 to US11 region or modified vaccinia virus Ankara expressing individual viral genes.

Authors:  Naeem Khan; Rachel Bruton; Graham S Taylor; Mark Cobbold; Thomas R Jones; Alan B Rickinson; Paul A H Moss
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.